AI assistant
EKF DIAGNOSTICS HOLDINGS PLC — Director's Dealing 2014
May 8, 2014
7617_dirs_2014-05-08_a3117af4-62e7-475b-9159-4dfb91c895ae.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 6177G
EKF Diagnostics Holdings PLC
08 May 2014
EKF Diagnostics Holdings plc
("EKF", the "Company")
Director / PDMR Shareholding
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that Directors of the Company have today made the following share purchases:
| Director | No. of ordinary shares purchased | Purchase price | Total shareholding before purchase | Total shareholding following purchase | Percentage of issued share capital |
| Julian Baines, Chief Executive Officer | 100,000 | 25.07p | 1,621,955 | 1,721,955 | 0.41% |
| David Evans, Executive Chairman | 100,000 | 25.07p | 1,605,753 | 1,705,753 | 0.40% |
| Paul Foulger, Chief Financial Officer | 50,000 | 25.07p | 3,438,589 | 3,488,589 | 0.83% |
| Richard Evans, Chief Operating Officer | 25,000 | 25.07p | 153,842 | 178,842 | 0.04% |
| Adam Reynolds, Non-Executive Director | 25,000 | 25.07p | 3,204,724 | 3,229,724 | 0.77% |
| Kevin Wilson, Non-Executive Director | 50,000 | 25.07p | 617,846 | 667,846 | 0.16% |
Enquiries:
| EKF Diagnostics Holdings plc | Tel: 029 2071 0570 | ||
| Julian Baines, CEO | Mob: 07788 420 859 | ||
| Canaccord Genuity Limited Nominated Adviser/Corporate Broking |
Tel: 020 7523 8350 | ||
| Lucy Tilley /Julian Feneley /Henry Fitzgerald-O'Connor /Chris Connors | |||
| Walbrook PR Limited | Tel: 020 7933 8780 | ||
| Paul McManus | Mob: 07980 541 893 or [email protected] | ||
| Lianne Cawthorne | Mob: 07584 391 303 or [email protected] | ||
About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com
EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.
The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.
In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.
In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market for a total consideration of $4.0m (c.£2.4m). In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBDGDUIGGBGSI